Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is a growing problem without an effective treatment, presenting as necrotic bone sections exposed via lesions in the overlying soft tissue. There is currently a lack of clarity on how the factors involved in MRONJ development and progression contribute to disease prognosis and outcomes. Bisphosphonates (BPs), the most common cause of MRONJ, affect bone remodeling, angiogenesis, infection, inflammation and soft tissue toxicity, all of which contribute to MRONJ development. This article reviews the cellular mechanisms through which BPs contribute to MRONJ pathology, with a focus on the effects on cells of the oral mucosa. BPs have been shown to reduce cell viability, reduce proliferation, and increase apoptosis in oral keratinocytes and fibroblasts. BPs have also been demonstrated to reduce epithelial thickness and prevent epithelial formation in three-dimensional tissue engineered models of the oral mucosa. This combination of factors demonstrates how BPs lead to the reduced wound healing seen in MRONJ and begins to uncover the mechanisms through which these effects occur. The evidence presented here supports identification of targets which can be used to develop novel treatment strategies to promote soft tissue wound healing and restore mucosal coverage of exposed bone in MRONJ.

Highlights

  • Medication-related osteonecrosis of the jaw (MRONJ) is a disease that presents as necrotic bone exposed via lesions in the soft tissues, and is currently without an effective treatment [1]

  • When cells were pre-treated with 100 μM for 72 h prior to the experiment was any effect seen, and this concentration was reported to be toxic at this exposure time in the same article [55]. Whilst these results suggest effect of BPs on cell migration there are limitations in the experimental design which reduce the reliability of this data

  • All showed decrease despite differences in concentration and time points [4, 51, 53, 56, 61,62,63,64,65,66,67,68] Increase 10 μM−24 h MTT

Read more

Summary

Introduction

Medication-related osteonecrosis of the jaw (MRONJ) is a disease that presents as necrotic bone exposed via lesions in the soft tissues, and is currently without an effective treatment [1]. It is encountered in patients receiving anti-resorptive or anti-angiogenic medications, most often in patients receiving bisphosphonates (BPs), used to treat osteoporosis, bony metastases and hypercalcaemia of malignancy. BPs are the most commonly prescribed antiresorptives worldwide [3] with over 190 million prescriptions for oral BPs estimated to have been dispensed worldwide since their first clinical use in 1969 [4]. 15% of patients treated for metastases with BPs are estimated to develop MRONJ [7] and there is an urgent unmet clinical need to improve outcomes for MRONJ patients

Objectives
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call